Resources for Patients and their Families
Request Free Guide

Mesothelioma Doctors

Philip D. Bonomi, MD

Dr. Bonomi
Chicago, IL

Dr. Philip D. Bonomi

Medical Oncologist

Rush University Cancer Center

1725 West Harrison Street
Professional Building, Suite 1010

Chicago, IL 60612

Need Help Contacting This Doctor?

Dr. Bonomi is board certified in internal medicine and medical oncology. His primary area of interest is within the field of thoracic and cardiothoracic oncology, with specialties in lung cancer and mesothelioma. The majority of Dr. Bonomi’s research interest is in the field of lung cancer treatment and detection.

He is also a professor within the Rush Medical College at Rush University. With more than 20 years of experience, Dr. Bonomi brings his clinical expertise with him into the classroom. Dr. Bonomi has also authored or co-authored over 150 publications, primarily in the field of small-cell lung cancer detection and survival-rate improvements, sharing his vast knowledge with others in the field.

Main Specialty: Medical Oncology

Other Interests & Specialties: Mesothelioma, lung cancer, hematologic oncology, general oncology, thoracic cancer and internal medicine.

Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Certification in Medical Oncology, America’s Top Doctor, America's Top Doctor for Cancer

Education & Experience:

The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. Journal of Thoracic Oncology. June 2016;11(6):808-818. doi: 10.1016/j.jtho.2016.03.002

Clinician Perspectives on Current Issues in Lung Cancer Drug Development. Journal of Thoracic Oncology. September 2016;11(9):1387-1396. doi: 10.1016/j.jtho.2016.05.009

Implications of key trials in advanced nonsmall cell lung cancer. Cancer. March 2010;116(5):1155-1164. doi: 10.1002/cncr.24815

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. Journal of Clinical Oncology. July 2009;27(20):3284-3289. doi: 10.1200/JCO.2008.20.8181

Author: Linda Molinari

Editor in Chief, Mesothelioma Cancer Alliance

Linda Molinari

Reviewer: Annette Charlevois

Patient Support Coordinator

Annette Charlevois
Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To:

Legal Rights Information Guide Free Guide Request Free Guide Free Mesothelioma Guide Free 2019 Mesothelioma Guide